{"schema_version":"secwatch.filing_event.v1","accession":"0001178913-26-002393","form_type":"8-K","ticker":"SLXN","cik":"0002022416","company_name":"Silexion Therapeutics Corp","filed_at":"2026-05-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:33.394560+00:00","generated_at":"2026-05-14T23:35:30.379252+00:00","sec_items":["5.03","5.07","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Silexion shareholders approve 50M share increase, expanded equity plan, and 1-for-10 reverse split","bullets":["Authorized shares increased from 9M to 59M via Memorandum Amendment effective May 5, 2026.","Equity incentive plan evergreen provision raised from 5% of outstanding to pool of 10% fully diluted shares annually.","Reverse stock split at 1-for-10 approved; can be reduced to maintain Nasdaq minimum public float.","All three proposals passed with ~61% of votes in favor at reconvened meeting with 40.2% quorum."],"urls":{"canonical":"https://secwatch.observer/filing/0001178913-26-002393","json":"https://secwatch.observer/filing/0001178913-26-002393.json","markdown":"https://secwatch.observer/filing/0001178913-26-002393.md","text":"https://secwatch.observer/filing/0001178913-26-002393.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2022416/000117891326002393/0001178913-26-002393-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2022416/000117891326002393/zk2635202.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-14T23:35:30.379252+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a720e5189c7c3dcf76ab27cf962c48097d204e39","claim":"Silexion Therapeutics Corp: Increase in authorized share capital from $121,500 divided into 9,000,000 ordinary shares to $796,500 divided into 59,000,000 ordinary shares (effective 2026-05-05).","evidence_excerpt":"At the extraordinary general meeting of Silexion Therapeutics Corp (the “ Company ”) originally held on April 28, 2026 and reconvened on May 5, 2026 (the “ Meeting ”), the shareholders of the Company duly approved a resolution serving as an effective amendment to paragraph 5 of the Company’s amended and restated memorandum of association (the “ Memorandum Amendment”) , which increased the Company’s authorized share capital, as described in Item 5.07 below.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/2022416/000117891326002393/0001178913-26-002393-index.htm","confidence":0.9}],"comparable_filings":[{"accession":"0000943374-26-000219","ticker":"DCOM","company_name":"Dime Community Bancshares, Inc. /NY/","filed_at":"2026-06-01T20:02:33+00:00","headline":"Dime Commercial Bancshares name change effective; three executives amend employment agreements","event_type":"other_material","sec_items":["5.02","5.03","5.07","9.01"],"materiality_score":0.55,"calibrated_materiality_score":0.55,"match_reasons":["same fact type: governance_change","same SEC item: 5.03, 5.07, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0000943374-26-000219","json":"https://secwatch.observer/filing/0000943374-26-000219.json","markdown":"https://secwatch.observer/filing/0000943374-26-000219.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/846617/000094337426000219/0000943374-26-000219-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/846617/000094337426000219/form8k_052826.htm"},"side_by_side_evidence":{"fact_type":"governance_change","source_excerpt":"At the extraordinary general meeting of Silexion Therapeutics Corp (the “ Company ”) originally held on April 28, 2026 and reconvened on May 5, 2026 (the “ Meeting ”), the shareholders of the Company duly approved a resolution serving as an effective amendment to paragraph 5 of the Company’s amended and restated memorandum of association (the “ Memorandum Amendment”) , which increased the Company’s authorized share capital, as described in Item 5.07 below.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/2022416/000117891326002393/0001178913-26-002393-index.htm","comparable_excerpt":"On May 28, 2026, the Company filed with the Department of State of the State of New York a Certificate of Amendment to Certificate of Incorporation to change our corporate name from Dime Community Bancshares, Inc. to Dime Commercial Bancshares, Inc., effective immediate.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/846617/000094337426000219/0000943374-26-000219-index.htm"}},{"accession":"0001213900-26-053305","ticker":"CLRCF","company_name":"ClimateRock","filed_at":"2026-05-07T23:59:59+00:00","headline":"ClimateRock shareholders approve extension to November 2, 2026 and redeem 4,543 shares for ~$59.9 million","event_type":"other_material","sec_items":["5.03","5.07","9.01"],"materiality_score":0.6,"calibrated_materiality_score":0.6,"match_reasons":["same fact type: governance_change","same SEC item: 5.03, 5.07, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-053305","json":"https://secwatch.observer/filing/0001213900-26-053305.json","markdown":"https://secwatch.observer/filing/0001213900-26-053305.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1903392/000121390026053305/0001213900-26-053305-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1903392/000121390026053305/ea0289583-8k_climate.htm"},"side_by_side_evidence":{"fact_type":"governance_change","source_excerpt":"At the extraordinary general meeting of Silexion Therapeutics Corp (the “ Company ”) originally held on April 28, 2026 and reconvened on May 5, 2026 (the “ Meeting ”), the shareholders of the Company duly approved a resolution serving as an effective amendment to paragraph 5 of the Company’s amended and restated memorandum of association (the “ Memorandum Amendment”) , which increased the Company’s authorized share capital, as described in Item 5.07 below.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/2022416/000117891326002393/0001178913-26-002393-index.htm","comparable_excerpt":"Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. The disclosure contained in","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1903392/000121390026053305/0001213900-26-053305-index.htm"}},{"accession":"0001690820-26-000039","ticker":"CVNA","company_name":"CARVANA CO.","filed_at":"2026-05-06T23:59:59+00:00","headline":"Carvana stockholders approve 5-for-1 stock split, adopt new 2026 incentive plan","event_type":"other_material","sec_items":["5.02","5.03","5.07","9.01"],"materiality_score":0.65,"calibrated_materiality_score":0.65,"match_reasons":["same fact type: governance_change","same SEC item: 5.03, 5.07, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001690820-26-000039","json":"https://secwatch.observer/filing/0001690820-26-000039.json","markdown":"https://secwatch.observer/filing/0001690820-26-000039.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1690820/000169082026000039/0001690820-26-000039-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1690820/000169082026000039/cvna-20260505.htm"},"side_by_side_evidence":{"fact_type":"governance_change","source_excerpt":"At the extraordinary general meeting of Silexion Therapeutics Corp (the “ Company ”) originally held on April 28, 2026 and reconvened on May 5, 2026 (the “ Meeting ”), the shareholders of the Company duly approved a resolution serving as an effective amendment to paragraph 5 of the Company’s amended and restated memorandum of association (the “ Memorandum Amendment”) , which increased the Company’s authorized share capital, as described in Item 5.07 below.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/2022416/000117891326002393/0001178913-26-002393-index.htm","comparable_excerpt":"At the Annual Meeting, the Company's stockholders approved an amendment (the \"Amendment\") to the Company's Amended and Restated Certificate of Incorporation to effect a five-for-one forward stock split of the Company's Class A common stock and Class B common stock (the \"Stock Split\") and to proportionately increase the number of authorized shares of Class A common stock and Class B common stock (the \"Authorized Share Increase\").","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1690820/000169082026000039/0001690820-26-000039-index.htm"}},{"accession":"0001829126-26-004646","ticker":"LEGT","company_name":"Legato Merger Corp. III","filed_at":"2026-05-06T23:59:59+00:00","headline":"Legato Merger Corp. III shareholders approve extension to August 8, 2026 for Einride business combination","event_type":"other_material","sec_items":["2.03","5.07","5.03","9.01"],"materiality_score":0.6,"calibrated_materiality_score":0.6,"match_reasons":["same fact type: governance_change","same SEC item: 5.03, 5.07, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001829126-26-004646","json":"https://secwatch.observer/filing/0001829126-26-004646.json","markdown":"https://secwatch.observer/filing/0001829126-26-004646.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/2002038/000182912626004646/0001829126-26-004646-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2002038/000182912626004646/legatomerger3_8k.htm"},"side_by_side_evidence":{"fact_type":"governance_change","source_excerpt":"At the extraordinary general meeting of Silexion Therapeutics Corp (the “ Company ”) originally held on April 28, 2026 and reconvened on May 5, 2026 (the “ Meeting ”), the shareholders of the Company duly approved a resolution serving as an effective amendment to paragraph 5 of the Company’s amended and restated memorandum of association (the “ Memorandum Amendment”) , which increased the Company’s authorized share capital, as described in Item 5.07 below.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/2022416/000117891326002393/0001178913-26-002393-index.htm","comparable_excerpt":"As previously disclosed, on November 12, 2025, Legato Merger Corp. III, a Cayman Islands exempted company (the “Company”), Einride AB, a limited liability company formed under the laws of Sweden (“Einride”), and Einride Cayman Sub Limited, a Cayman Islands exempted company and a direct, wholly-owned subsidiary of Einride (“Merger Sub”), entered into a Business Combination Agreement (“BCA”). Pursuant to the BCA, the Company will merge with and into Merger Sub, with Merger Sub surviving the merger (“Merger”). As a result of the Merger, Merger Sub will continue as a direct, wholly-owned subsidiary of Einride, with the shareholders of the Company becoming shareholders of Einride. On May 5, 2026, the Company held an extraordinary general meeting (the “Meeting”) to approve the following resolutions: ● to resolve as a special resolution, that the Company’s amended and restated memorandum and articles of association as adopted by special resolution dated February 5, 2024 with effect from Febru","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/2002038/000182912626004646/0001829126-26-004646-index.htm"}},{"accession":"0001609550-26-000026","ticker":"INSP","company_name":"Inspire Medical Systems, Inc.","filed_at":"2026-05-05T23:59:59+00:00","headline":"Inspire Medical shareholders approve declassification, 2.6M-share increase to equity plan","event_type":"other_material","sec_items":["5.02","5.07","5.03","9.01"],"materiality_score":0.55,"calibrated_materiality_score":0.55,"match_reasons":["same fact type: governance_change","same SEC item: 5.03, 5.07, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001609550-26-000026","json":"https://secwatch.observer/filing/0001609550-26-000026.json","markdown":"https://secwatch.observer/filing/0001609550-26-000026.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1609550/000160955026000026/0001609550-26-000026-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1609550/000160955026000026/insp-20260430.htm"},"side_by_side_evidence":{"fact_type":"governance_change","source_excerpt":"At the extraordinary general meeting of Silexion Therapeutics Corp (the “ Company ”) originally held on April 28, 2026 and reconvened on May 5, 2026 (the “ Meeting ”), the shareholders of the Company duly approved a resolution serving as an effective amendment to paragraph 5 of the Company’s amended and restated memorandum of association (the “ Memorandum Amendment”) , which increased the Company’s authorized share capital, as described in Item 5.07 below.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/2022416/000117891326002393/0001178913-26-002393-index.htm","comparable_excerpt":"On May 1, 2026, the Company filed a Certificate of Amendment to the Certificate of Incorporation (the “Certificate of Amendment”) with the Secretary of State of the State of Delaware, which became effective upon filing.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1609550/000160955026000026/0001609550-26-000026-index.htm"}},{"accession":"0001628280-26-030618","ticker":"AAWH","company_name":"Ascend Wellness Holdings, Inc.","filed_at":"2026-05-05T23:59:59+00:00","headline":"Ascend Wellness Holdings completes Class B conversion and annual meeting","event_type":"other_material","sec_items":["3.03","5.03","5.07","9.01"],"materiality_score":0.6,"calibrated_materiality_score":0.6,"match_reasons":["same fact type: governance_change","same SEC item: 5.03, 5.07, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-030618","json":"https://secwatch.observer/filing/0001628280-26-030618.json","markdown":"https://secwatch.observer/filing/0001628280-26-030618.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1756390/000162828026030618/0001628280-26-030618-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1756390/000162828026030618/aawh-20260429.htm"},"side_by_side_evidence":{"fact_type":"governance_change","source_excerpt":"At the extraordinary general meeting of Silexion Therapeutics Corp (the “ Company ”) originally held on April 28, 2026 and reconvened on May 5, 2026 (the “ Meeting ”), the shareholders of the Company duly approved a resolution serving as an effective amendment to paragraph 5 of the Company’s amended and restated memorandum of association (the “ Memorandum Amendment”) , which increased the Company’s authorized share capital, as described in Item 5.07 below.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/2022416/000117891326002393/0001178913-26-002393-index.htm","comparable_excerpt":"On May 5, 2026, the Company filed a Certificate of Retirement with the Secretary of State of the State of Delaware (the “Certificate of Retirement”) to effect the retirement of the 65,000 shares of Class B Common Stock that were issued but no longer outstanding following the Conversion. Pursuant to Section 243(b) of the DGCL, upon its effectiveness, the Certificate of Retirement had the effect of amending the Certificate of Incorporation to reduce the total number of authorized shares of common stock of the Company by 65,000, to 750,035,000, and to reduce the number of authorized shares of Class B Common Stock by 65,000, to 35,000.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1756390/000162828026030618/0001628280-26-030618-index.htm"}},{"accession":"0001104659-26-054940","ticker":"MRKR","company_name":"Marker Therapeutics, Inc.","filed_at":"2026-05-04T23:59:59+00:00","headline":"Marker Therapeutics shareholders approve increase in authorized shares from 30M to 130M","event_type":"other_material","sec_items":["5.03","5.07","9.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same fact type: governance_change","same SEC item: 5.03, 5.07, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-054940","json":"https://secwatch.observer/filing/0001104659-26-054940.json","markdown":"https://secwatch.observer/filing/0001104659-26-054940.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1094038/000110465926054940/0001104659-26-054940-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1094038/000110465926054940/tm2613511d1_8k.htm"},"side_by_side_evidence":{"fact_type":"governance_change","source_excerpt":"At the extraordinary general meeting of Silexion Therapeutics Corp (the “ Company ”) originally held on April 28, 2026 and reconvened on May 5, 2026 (the “ Meeting ”), the shareholders of the Company duly approved a resolution serving as an effective amendment to paragraph 5 of the Company’s amended and restated memorandum of association (the “ Memorandum Amendment”) , which increased the Company’s authorized share capital, as described in Item 5.07 below.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/2022416/000117891326002393/0001178913-26-002393-index.htm","comparable_excerpt":"the Company’s stockholders approved an amendment to the Company’s Certificate of Incorporation, as amended, to increase the number of authorized shares of our Common Stock from 30,000,000 shares of Common Stock to 130,000,000 shares of Common Stock (the “ Charter Amendment ”).","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1094038/000110465926054940/0001104659-26-054940-index.htm"}},{"accession":"0001104659-26-053557","ticker":"CWEN","company_name":"Clearway Energy, Inc.","filed_at":"2026-05-01T23:59:59+00:00","headline":"Clearway Energy eliminates Class A stock; converts all shares to reduced-vote Class C","event_type":"other_material","sec_items":["1.01","3.03","5.03","5.07","7.01","9.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same fact type: governance_change","same SEC item: 5.03, 5.07, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-053557","json":"https://secwatch.observer/filing/0001104659-26-053557.json","markdown":"https://secwatch.observer/filing/0001104659-26-053557.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1567683/000110465926053557/0001104659-26-053557-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1567683/000110465926053557/tm2613249d1_8k.htm"},"side_by_side_evidence":{"fact_type":"governance_change","source_excerpt":"At the extraordinary general meeting of Silexion Therapeutics Corp (the “ Company ”) originally held on April 28, 2026 and reconvened on May 5, 2026 (the “ Meeting ”), the shareholders of the Company duly approved a resolution serving as an effective amendment to paragraph 5 of the Company’s amended and restated memorandum of association (the “ Memorandum Amendment”) , which increased the Company’s authorized share capital, as described in Item 5.07 below.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/2022416/000117891326002393/0001178913-26-002393-index.htm","comparable_excerpt":"Following the Class A Conversion, on May 1, 2026, the Company filed with the Delaware Secretary of State a certificate of retirement pursuant to Section 243 of the DGCL (the “Certificate of Retirement”) to retire all shares of Class A common stock converted in the Class A Conversion, which also had the effect of amending the Amended Charter to (i) reduce the total number of authorized shares of Class A common stock from 34,613,853 to zero, (ii) reduce the total number of authorized shares of capital stock of the Company from 2,544,613,853 to 2,510,000,000 and (iii) eliminate from the Amended Charter all references to the Class A common stock (collectively, the “Class A Retirement”).","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1567683/000110465926053557/0001104659-26-053557-index.htm"}}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}